



Universiteit  
Leiden  
The Netherlands

## Metabolomics to predict progression in chronic kidney disease

Dekker, S.E.I.

### Citation

Dekker, S. E. I. (2024, November 7). *Metabolomics to predict progression in chronic kidney disease*. Retrieved from <https://hdl.handle.net/1887/4107624>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4107624>

**Note:** To cite this publication please use the final published version (if applicable).

# Metabolomics to predict progression in chronic kidney disease

Shosha E.I. Dekker

Metabolomics to predict progression in chronic kidney disease

ISBN: 978-94-6506-288-4

Cover design: Jeroen Reith, [persoonlijkproefschrift.nl](http://persoonlijkproefschrift.nl)

Lay-out: Anna Bleeker, [persoonlijkproefschrift.nl](http://persoonlijkproefschrift.nl)

Printing: Ridderprint BV, [www.ridderprint.nl](http://www.ridderprint.nl)

Copyright © S.E.I. Dekker, 2024 All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronically, mechanically, by photography, by recording, or otherwise, without prior written permission of the author.

# Metabolomics to predict progression in chronic kidney disease

Proefschrift

ter verkrijging van  
de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op donderdag 7 november 2024  
klokke 11.30 uur

door

**Shosha Ellen Immertina Dekker**

geboren te Leiden  
in 1990

**Promotor**

Prof. dr. J.W. de Fijter

**Copromotors**

Dr. O.M. Mayboroda

Dr. D. Soonawala

**Leden promotiecommissie**

Prof. dr. C. van Kooten

Prof. dr. D.J.M. Peters

Prof. dr. M. Vervloet (Radboud universitair medisch centrum)

Dr. E.J. Want (Imperial College London)

## Table of contents

<b>Chapter 1</b>	General introduction	7
<b>Chapter 2</b>	Urinary biomarkers as predictors for disease progression in CKD patients with ADPKD: a narrative review	19
<b>Chapter 3</b>	Urinary tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 do not correlate with disease severity in ADPKD patients <i>Kidney International Reports 2019</i>	41
<b>Chapter 4</b>	Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease <i>PLoS ONE 2020</i>	61
<b>Chapter 5</b>	Change in urinary myoinositol/citrate ratio associates with progressive loss of renal function in ADPKD patients <i>American Journal of Nephrology 2022</i>	87
<b>Chapter 6</b>	Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide <i>European Journal of Clinical Investigation 2024</i>	113
<b>Chapter 7</b>	Summary and general discussion	143
<b>Chapter 8</b>	Nederlandse samenvatting	153
<b>Chapter 9</b>	List of publications	161
	Curriculum vitae	164
	Dankwoord	165